ReviewLife (Basel, Switzerland)2026
GABRD as an Emerging Oncogene: Exploring Functions and Therapeutic Implications Across Cancers.
Review in Life (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The γ-aminobutyric acid type A receptor subunit delta (GABRD) constitutes a critical component of the principal inhibitory neurotransmitter receptors within the brain. Recent investigations have revealed aberrant expression of GABRD across a spectrum of non-neural malignancies, including breast, colorectal, and gastric cancers, wherein it exhibits a multifaceted and paradoxical role in oncogenesis. This review delineates the biological characteristics of GABRD and its involvement in cancer pathophysiology. Specifically, the activation of GABRD is implicated in the initiation of key downstream signaling pathways that facilitate the proliferation, invasion, and metastasis of cancer cells. Additionally, the review examines the interaction between GABRD and the tumor microenvironment. Furthermore, it provides an analysis of the diverse roles and mechanisms attributed to GABRD across various cancer types. In conclusion, this review encapsulates the current advancements in understanding the oncogenic functions of GABRD and deliberates on its potential and challenges as a novel target for therapeutic intervention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.